Banaschewski Tobias, Belsham Brendan, Bloch Michael H, Ferrin Maite, Johnson Mats, Kustow James, Robinson Sarah, Zuddas Alessandro
Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany.
Private practice, Johannesburg, South Africa.
Nutr Health. 2018 Dec;24(4):279-284. doi: 10.1177/0260106018772170. Epub 2018 Jun 19.
While pharmacotherapy and psychosocial interventions are recommended as the primary frontline treatment for attention deficit hyperactivity disorder (ADHD), alternative approaches to managing ADHD are becoming increasingly popular among patients and their families. Supplementation with polyunsaturated fatty acids (PUFAs) is an example of this. PUFA supplementation is not recommended by guidelines for managing ADHD; however, patients may still decide to use it. To provide direction to healthcare professionals (HCPs) managing ADHD, eight international experts in the field of adult and child ADHD came together for the Continuum Education Board: Omega Supplements in ADHD meeting. This commentary summarises the panel's consensus that current evidence suggests PUFA supplementation has a small beneficial effect on behaviour in children with ADHD, and that further high-quality research is needed to clearly evaluate and define its role in the management of ADHD of children, adolescents and adults. The panel concluded that in cases where patients use PUFA supplementation, HCPs should be comfortable explaining the potential gains that they may have and their possible side effects. The panel also concluded HCPs should not reinforce the idea that PUFA supplementation should replace treatment approaches with a more robust evidence base for managing ADHD.
虽然药物治疗和心理社会干预被推荐为注意力缺陷多动障碍（ADHD）的主要一线治疗方法，但管理ADHD的替代方法在患者及其家庭中越来越受欢迎。补充多不饱和脂肪酸（PUFA）就是一个例子。管理ADHD的指南不推荐补充PUFA；然而，患者仍可能决定使用它。为了给管理ADHD的医疗保健专业人员（HCP）提供指导，八位成人和儿童ADHD领域的国际专家齐聚Continuum教育委员会：ADHD中的欧米伽补充剂会议。本评论总结了专家小组的共识，即目前的证据表明补充PUFA对ADHD儿童的行为有微小的有益影响，并且需要进一步的高质量研究来明确评估和界定其在儿童、青少年和成人ADHD管理中的作用。专家小组得出结论，在患者使用PUFA补充剂的情况下，HCP应能够自如地解释他们可能获得的潜在益处及其可能的副作用。专家小组还得出结论，HCP不应强化补充PUFA应取代有更充分证据基础的ADHD管理治疗方法这一观点。
